Sign Up for a Free Account
  • Updated 12.27.2023
  • Released 09.22.2005
  • Expires For CME 12.27.2026

Seizures associated with eclampsia



Preeclampsia or eclampsia is a multisystem disorder of pregnancy and the puerperium. Preeclampsia occurs after the twentieth week of gestation and is characterized by hypertension, proteinuria, and pathologic edema. Eclampsia is defined as the occurrence of generalized seizures in a woman with preexisting preeclampsia. Many reports have indicated that SARS-CoV-2 infection adversely affects pregnancy and can predispose pregnant women to preeclampsia and possibly to eclampsia as well. Approximately 10% to 15% of maternal deaths are associated with preeclampsia and eclampsia. Although the incidence of eclampsia and its complications have decreased significantly in developed countries, the incidence is still high in poor countries. The latest data from the United States indicated an approximately 10% decline in the risk of eclampsia between 2009 to 2017. Eclampsia occurring more than 48 hours, but less than 4 weeks, after delivery is known as late postpartum eclampsia. Postpartum preeclampsia or eclampsia may present without a history of preeclampsia during the pregnancy. Visual disturbances, epigastric pain, headache, and edema are four of the most frequent symptoms that can predict imminent eclampsia in ladies with preeclampsia. In eclampsia, reversible posterior leukoencephalopathy syndrome is an increasingly recognized cause of seizures, cortical blindness, and encephalopathy. In addition to posterior leukoencephalopathy syndrome, neuroimaging may reveal cerebral edema, infarction, cerebral venous thrombosis, and cerebral hemorrhage. Magnesium sulfate is the treatment of choice for the control of recurrent eclamptic seizures in pregnant women. In a study, a low-dose regimen of magnesium sulfate appeared comparable to the “standard” dose regimen. The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine recommend only short-term (usually less than 48 hours) use of magnesium sulfate. If given in excess, magnesium sulfate has a neuromuscular junction-blocking effect, and such patients could manifest with “pseudocoma.” Early combined treatment of critically raised blood pressure with intravenous antihypertensive drugs and magnesium sulfate is associated with a reduction in the frequency of eclampsia and severe maternal morbidity. The long-term risk of seizures in an eclamptic patient is low; however, preeclampsia/eclampsia is associated with increased risk of cognitive decline in later life. In this article, the author reviews the clinical features, epidemiology, pathophysiology, differential diagnosis, complications, and principles of treatment.

Key points

• Preeclampsia is a multisystem disorder occurring after the 20th week of gestation that is characterized by hypertension, proteinuria, and pathologic edema.

• Eclampsia is defined as the occurrence of generalized seizures in a woman with preexisting preeclampsia.

• The onset of eclamptic convulsions can be antepartum, intrapartum, postpartum, or late postpartum (48 hours after delivery).

• Brain MRI reveals bilateral, symmetrical, reversible hypodense lesions in the white matter of parietooccipital regions of the brain.

• Magnesium sulfate is considered the treatment of choice.

• Reduction in eclampsia can be achieved by good prenatal care, early detection of preeclampsia, and prophylactic use of magnesium sulfate in preeclampsia.

Historical note and terminology

Ancient accounts of eclampsia and childbirth are available in medical writings of Egyptian, Indian, Chinese, and Greek civilizations. The term “eclampsia” was used by ancient Greeks. Prior to the 18th century, the term “eclampsia” was used to refer to the visual phenomenon associated with this disorder. In 1673, Mauriceau, a noted French obstetrician, gave a detailed description of the subject in his book, and he believed that eclampsia improved after delivery (19; 47). The view that salt plays a crucial role in eclampsia was given by De Snoo (1877-1949), a Dutch obstetrician. In 1840, PF Rayer, a French pathologist, for the first time noted proteinuria in pregnant women. However, the discovery of proteinuria in eclampsia was made by LC Lever of London and JY Simpson of Scotland in 1843. Lever recommended periodic testing of urine for proteinuria in pregnancy. Georg Schmorl, in 1893, first demonstrated the presence of fetal cells in the maternal body and emphasized the importance of the placenta in eclampsia (52). Until the middle of the 19th century, treatment of eclampsia was mostly by physical methods and expediting the delivery. Physical methods were bleeding by venesection, blistering, immersion in hot water, and hot compress in kidney regions. Bleeding was considered an important procedure to get rid of toxins, and a large amount of blood used to be let out. Opening of the temporal artery had been advocated for bloodletting. By the end of the 19th century, bloodletting for eclampsia had generally been abandoned, replaced chiefly by expeditious delivery as the treatment of choice. Animal experimental studies conducted at the turn of the century resulted in the use of magnesium sulfate as an anticonvulsant in humans. As early as 1906, magnesium sulfate was injected intrathecally to prevent eclamptic seizures. Because of reports that intramuscular magnesium sulfate-controlled convulsions associated with tetanus, a similar regimen was used by Lazard and Dorsett in 1926 to prevent recurrent seizures in women with eclampsia. In 1933, the drug was given intravenously to hundreds of women with preeclampsia and eclampsia at the Los Angeles General Hospital (19; 74).

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125